WIPO Arbitration and Mediation Center
ADMINISTRATIVE PANEL DECISION
F. Hoffmann-La Roche AG v. JIMMY BAILEY LTD.
Case No. D2011-0735
1. The Parties
The Complainant is F. Hoffmann-La Roche AG, Basel, Switzerland, represented by John J. Kelly and Associates, LLC, New York, NY.
The Respondent is JIMMY BAILEY LTD, Chicago, Illinois, represented by John J. Kelly and Associates, LLC, Chicago, Illinois.
2. The Domain Name and Registrar
The disputed domain name <xenical-buy.com> is registered with the Domain Name Registrar, Registration # 11/5/2010.
3. Procedural History
The Complaint was filed with the WIPO Arbitration and Mediation Center (the “Center”) on June 13, 2011. On June 13, 2011, the Center transmitted by email to the Registrar a request for registrar verification in connection with the disputed domain name. On June 13, 2011, the Registrar transmitted by email to the Center its verification response confirming that the Respondent is listed as the registrant and providing the contact details for the administrative and technical contact. The Center verified that the Complaint satisfied the formal requirements of the Uniform Domain Name Dispute Resolution Policy (the “Policy”), the Rules for Uniform Domain Name Dispute Resolution Policy (the “Rules”), and the WIPO Supplemental Rules for Uniform Domain Name Dispute Resolution Policy (the “Supplemental Rules”).
In accordance with the Rules, paragraphs 2(a) and 4(a), the Center formally notified the Respondent of the Complaint, and the proceedings commenced on June 17, 2011. In accordance with the Rules, paragraph 5(a), the due date for Response was June 19, 2011. The Respondent did not submit any response. Accordingly, the Center notified the Respondent’s default on June 20, 2011.
The Center appointed John J. Kelly as the sole panelist in this matter on June 20, 2011. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7.
4. Factual Background
The Complainant is a pharmaceutical company in the United States, Canada, Mexico, Germany, and Australia.
The Respondent owns the domain name <xenical-buy.com> and the domain name <xenical-buy.com> registered on the Registrar’s website. The Domain Name is identical or confusingly similar to the Complainant’s trademark and is registered on the Respondent’s website.
The Respondent has no rights or legitimate interest in the Domain Name. The disputed domain name and the Respondent’s website are confusingly similar to the Complainant’s trademark.
5. Parties’ Contentions
A. Complainant
The Complainant contends that the Respondent has no rights or legitimate interest in the Domain Name, as the disputed domain name is identical or confusingly similar to the Complainant’s trademark and is registered on the Respondent’s website.
The Complainant also contends that the Respondent has no rights or legitimate interest in the Domain Name. The Complainant is relying on Paragraph 4(c) of the Policy to indicate that the Respondent has no rights or legitimate interest in the Domain Name. The Complainant is also relying on Paragraph 4(e) of the Policy to indicate that the Respondent has no rights or legitimate interest in the Domain Name.
The Complainant also contends that the Domain Name is confusingly similar to the Complainant’s trademark and is confusingly similar to the Respondent’s website and is confusingly similar to the Complainant’s mark.
The Food and Drug Administration announced Thursday that the agency had approved the use of a 120-milligram capsule of the weight-loss drug, Orlistat, to help people with type 2 diabetes. The capsule contains the active ingredient Xenical, which is used to help people who are unable to lose weight with diet and exercise.
The FDA’s decision, which was made after extensive clinical testing and a public comment period, was expected to cause public outrage in the wake of the deaths of at least two people who died after taking the drug, said Janet Woodcock, the FDA’s commissioner.
“The FDA’s announcement is a blow to public trust in the drug and to the well-being of all Americans,” Woodcock told The Associated Press in an interview. “The FDA’s action sends a clear message to doctors and patients that this medication is not a magic bullet for improving health or for helping people.”
The move comes a day after several other agencies and the FDA had earlier issued a similar warning to Xenical that the drug had not been approved for use by the U. S. Food and Drug Administration.
In July, the FDA said the use of a 120-milligram capsule of Orlistat by patients taking it, orlistat, was contraindicated by the agency for people who were taking other weight-loss drugs, such as the type 2 diabetes drug, type 2 diabetes medicine metformin and weight-loss anti-diabetic medications metoprolol.
The FDA’s action, which took effect Wednesday, is part of an effort by the agency to tighten drug safety standards, including the weight-loss drugs, and to make the drug more widely available. FDA spokeswoman Kathryn McLeod said the agency is reviewing the action, but did not say when.
“We are reviewing the actions taken by the agency to determine whether or not we are approving the use of the 120-milligram capsule of Xenical in patients with type 2 diabetes,” Woodcock said. “We are also reviewing the actions taken by the FDA to make sure that it does not take a different course of action for this medication than the drug the agency is already taking it to treat the disease.”
The FDA’s decision is the latest in a series of changes that have made the drug a safer and more effective drug for treating obesity, which affects more than one in three Americans. Some of the changes came into effect in September, when the FDA approved the use of the drug for a restricted use period, when it was available in generic forms.
“We are pleased that the FDA has determined that the 120-milligram capsule of Xenical is safe and effective in the treatment of type 2 diabetes, and we are also pleased that the agency has taken a much closer look at other weight-loss drugs,” Woodcock said.
For instance, the FDA said the drug has been approved for use in patients who have not been prescribed Xenical by their physicians, and that it has also been approved for use in patients who are overweight and who are taking a diet and exercise program.
The drug has been approved for use in patients who are obese and have type 2 diabetes.
The agency said it will continue to monitor the progress of the drug, and to make final decisions when it comes time for the drug’s approval.
“We are committed to ensuring that the safety, effectiveness and appropriate use of Xenical are carefully considered during this approval process,” Woodcock said.
The FDA said it has made several changes in its drug safety information system to improve patient adherence to the drug, and to help drug manufacturers make more informed decisions. These changes include a warning about Xenical’s potential interaction with other drugs, a requirement that Xenical be taken at the lowest dose possible and changes to the Food and Drug Administration’s patient information system.
The FDA said it will review the information, and will update this information with the latest information.
The agency has also made several changes to its drug safety information system, including that patients taking the drug must tell their doctors about the side effects of the drugs and about the risks of taking the drug.
The drug has also been approved for use in patients who have diabetes and who are overweight, and the FDA said it has also been approved for use in patients who are obese and who are taking a diet and exercise program.
The FDA said it has reviewed the information from the FDA and has made several changes to the information, including one in the safety information system.
Xenical (orlistat) is an innovative weight loss medication that aids individuals in managing obesity by inhibiting the absorption of dietary fats in the intestine. Obesity is a significant health concern that increases the risk of various conditions, including heart disease, diabetes, and hypertension. Xenical offers a unique approach to weight management by preventing the breakdown and absorption of about 30% of the fat consumed in a meal, which is then excreted from the body. This reduction in fat absorption helps lower overall caloric intake, making it easier for individuals to lose weight and maintain a healthy lifestyle. When combined with a balanced diet and regular exercise, Xenical can significantly improve weight loss outcomes and reduce obesity-related health risks. It is a valuable tool for those struggling with weight management, providing support and efficacy in achieving long-term weight loss goals.
Before starting the Xenical treatment, individuals should discuss their medical history with a healthcare professional. They may be able to (1-2 weeks after beginning treatment) take advantage of Xenical as a weight-loss treatment by taking a 1-day multivitamin containing fat-soluble vitamins (A, D, E, and K). This helps improve the effectiveness of Xenical by preventing the absorption of dietary fats. Additionally, individuals (3-5 years of age), in collaboration with their healthcare provider, may be able to take advantage of Xenical as part of a weight loss program to help them avoid maintaining a weight-related condition such as diabetes. Should any health concerns arise, contact a healthcare professional.
For individuals with a history of cardiovascular diseases, liver or kidney problems, or individuals with a history of polycystic ovary syndrome pct, (lithium), or thyroid disorders, Xenical can be an effective weight loss treatment. By preventing the breakdown and absorption of about 30% of the fat consumed in a meal, Xenical helps lower overall caloric intake, which can lead to a reduction in obesity-related complications. This can potentially lead to a reversal of weight loss after 2 years of treatment. Remember, always consult with a healthcare professional before starting any weight loss treatment to ensure it is suitable for individual needs.
Xenical (Orlistat) is a revolutionary weight loss medication that aids individuals in managing obesity by preventing the absorption of dietary fats. With its unique formulation, Xenical helps to lower obesity-related complications, such as heart disease, diabetes, and hypertension. With its ability to enhance overall weight loss, Xenical helps to lower obesity-related costs, supports cardiovascular health, and reduces associated health risks for the individual. With its ability to lower obesity-related complications, Xenical helps to improve blood sugar levels, improve blood pressure management, and reduces associated health risks for the individual. With its ability to lower obesity-related costs, support cardiovascular health, and reduce associated health risks, Xenical can be an effective weight loss treatment for individuals struggling with obesity. With its unique formulation, Xenical helps to enhance overall weight loss, improve blood sugar levels, support cardiovascular health, and reduce associated health risks for the individual.Xenical (Orlistat) should be taken orally with a full glass of water. It can be taken with or without food, but it is recommended to take it at a fixed time each day to avoid taking it early in the day. Do not crush or chew the medication. Follow your doctor’s instructions regarding dosage and timing for the treatment to be effective. Do not exceed the prescribed dosage, and consult your healthcare professional if you experience any side effects. Xenical (Orlistat) is FDA-approved for weight loss in adults and adolescents ≥17 years of age and for obesity management in adults and children <17 years of age.
Xenical (Orlistat) is a combination medication composed of orlistat, a lipase inhibitor, and a sulfonamide anion. Orlistat blocks lipases, enzymes that break down fats, preventing them from being absorbed by the body. This reduces their absorption, which can lead to a decrease in fat absorption. Xenical (Orlistat) can assist in weight loss by inhibiting the absorption of dietary fats, thereby reducing the overall amount of fat consumed. It is not a disease-prevention medication and does not increase physical activity. It is also not recommended for individuals taking any medication known as monoamine oxidase inhibitors (MAOIs).
Xenical (Orlistat) is a prescription medication.
Xenical: Your Guide To Obesity Management
Xenical, a leading weight loss medication, has emerged as a beacon of hope for individuals dealing with and, which is a common issue in the medical field. In this, we will delve into the latest advancements in this area, shedding light on what you can expect from Xenical as a weight management solution. Whether you are seeking to boost your health or simply want to help reduce the weight of your body, Xenical offers a reliable solution that can make a significant difference in your overall health and well-being.
Introduction to Xenical
Xenical, also known as Xenical, is a prescription weight loss medication that is widely recognized for its effectiveness in reducing the weight of individuals struggling with weight loss. It belongs to a class of drugs known as lipase inhibitors, which work by preventing the absorption of fat in the body. By reducing the amount of fat absorbed from food, Xenical helps individuals maintain an overall body weight, ensuring their overall health and well-being.
When it comes to the science behind Xenical, it is important to understand its mechanism.
Stade de France Pharmacy